Acceptability and Determinants for Implementation of the EnzySystem, a Novel Near‐Patient Testing Platform for Haemophilia A
The results of this study support the further development of the EnzySystem for haemophilia A and highlight barriers that should be addressed to facilitate implementation.
Authors
- Tanja Hamacher (ORCID: https://orcid.org/0000-0001-9760-9143)
- Monique G.J.T.B. van Lier (ORCID: https://orcid.org/0000-0002-1166-6639)
- Amy D. Shapiro (ORCID: https://orcid.org/0000-0003-2821-7159)
- Saskia E.M. Schols (ORCID: https://orcid.org/0000-0003-2423-2829)
- Nicole M. A. Blijlevens (ORCID: https://orcid.org/0000-0002-1801-2072)
- Waander L. van Heerde (ORCID: https://orcid.org/0000-0001-7101-8775)
- Lisa van Engelshoven
- Aernoud P. Bavinck (ORCID: https://orcid.org/0000-0002-8448-9151)
- King Davis (ORCID: https://orcid.org/0009-0003-1272-1307)
Institutions
- Netherlands Institute for Innovative Ocular Surgery (NL)
- Radboud University Nijmegen (NL)
- Dalsa Corporation (CA)
- Radboud University Medical Center (NL)
- Innovative Solution In Space (Netherlands) (NL)
- Indiana Hemophilia and Thrombosis Center (US)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1111/hae.70191
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00